In a first-of-its-kind study, researchers with the University of Texas
MD Anderson Cancer Center found patients with Epithelial Ovarian Cancer
(EOC) treated with heard medicines known as beta-blockers lived longer.For the study, researchers examined the medical records of 1,425 women
with ovarian cancer treated between 2000 and 2010. Those given
beta-blockers along with chemotherapy survived up to three times longer
than those who didn’t receive the drugs.
"Beta-blockers treat a variety of conditions, such as heart disease,
high-blood pressure, glaucoma and migraines. They target a receptor
protein in heart muscle that causes the heart to beat harder and faster
when activated by stress hormones," said Anil Sood, M.D., a cancer
specialist at MD Anderson who led the study. "Our research has shown
that the same stress mechanisms impact ovarian cancer progression, so
these drugs could play a new role in cancer treatment."
This study adds to past research showing that stress hormones fuel the
progression of ovarian and other cancers, and that beta-blockers can
stifle that effect.
No comments:
Post a Comment